RJA
BDTX icon

Raymond James & Associates’s Black Diamond Therapeutics BDTX Stock Holding History

Raymond James & Associates’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23,635
Closed -$120K – 3974
2024
Q1 		$120K Buy
+23,635
New +$95.3K ﹤0.01% 3712
2021
Q1 		– Sell
-7,467
Closed -$239K – 4003
2020
Q4 		$239K Sell
7,467
-26
-0.3% -$854 ﹤0.01% 3271
2020
Q3 		$227K Buy
7,493
+333
+5% +$10.1K ﹤0.01% 3126
2020
Q2 		$302K Buy
+7,160
New +$264K ﹤0.01% 2920

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's BDTX Position: Q2 2024 in Review

Raymond James & Associates sold out of Black Diamond Therapeutics (BDTX) in Q2 2024, closing a stake of 23,635 shares — an estimated $120K sold.

Raymond James & Associates first reported a position in BDTX in Q2 2020 and held it in 4 quarters. The position peaked at $302K in Q2 2020. 90 funds tracked by Wall St. Rank hold BDTX as of Q2 2024.

  • Raymond James & Associates reported no remaining Black Diamond Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Raymond James & Associates sold 23,635 Black Diamond Therapeutics shares in Q2 2024, an estimated $120K.
  • Raymond James & Associates first reported a position in Black Diamond Therapeutics in Q2 2020 and held it in 4 quarters.
  • Raymond James & Associates's Black Diamond Therapeutics position peaked at $302K in Q2 2020.
  • 90 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2024.

Based on Raymond James & Associates's 13F filing for Q2 2024, filed 19 Jul 2024.